ZSAN Zosano Pharma Corporation

0.6
0  -1%
Previous Close 0.6
Open 0.61
52 Week Low 0.523
52 Week High 3.06
Market Cap $71,008,196
Shares 118,346,993
Float 115,507,626
Enterprise Value $65,222,236
Volume 1,042,165
Av. Daily Volume 2,517,625
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Qtrypta (M207)
Migraine
NDA Filing
NDA Filing
CRL announced October 21, 2020. NDA filing to be resubmitted following PK trial. PK trial data reported that treatment was generally well tolerated, consistent with previous studies. The preliminary data from the PK analysis showed that there were no outliers with unexpected high plasma concentrations of zolmitriptan, noted October 4, 2021. Granted Type C meeting with FDA.
Qtrypta (M207)
Migraine
Phase 3
Phase 3
Phase 3 trial data due released February 13, 2017 - primary endpoints met.
C213
Cluster headache
Phase 2/3
Phase 2/3
Phase 2/3 trial enrollment stopped to conserve resources.

Latest News

  1. FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano's microneedle patch system. Zosano's patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator.

    "We are pleased to have successfully formulated a COVID-19 vaccine candidate onto our microneedle patch system, which provides additional support for the potential of our microneedle patch technology," said Mahmoud Ameri, Ph.D., vice president of research and development…

    FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano's microneedle patch system. Zosano's patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator.

    "We are pleased to have successfully formulated a COVID-19 vaccine candidate onto our microneedle patch system, which provides additional support for the potential of our microneedle patch technology," said Mahmoud Ameri, Ph.D., vice president of research and development at Zosano. "We believe a COVID-19 vaccine candidate using our patch technology, if successfully developed and approved, may provide an alternative to traditional intramuscular injections. The formulated patches are also designed to be stable at room temperature, which we believe may enable easier and broader distribution without the burden of cold-chain storage."

    "This successful development milestone along with previously published data on the formulation and coating of an influenza vaccine on our transdermal patch is encouraging for the broader applicability of Zosano's technology," said Steve Lo, chief executive officer of Zosano. "While we continue to be focused on the potential resubmission of our M207 New Drug Application, we also continue to pursue non-dilutive and partnership opportunities to expand the potential use of our technology."

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits and potential uses of the company's microneedle patch technology, the potential benefits and availability of a Covid-19 vaccine candidate, the potential resubmission of the M207 New Drug Application, the potential benefits and availability of M207 for patients, the pursuit of non-dilutive and partnership opportunities to expand the potential use of our technology and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "scheduled," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company's ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

    Zosano Contacts:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    Zosano PR:

    Sylvia Wheeler or Alexandra Santos

     or  



    Primary Logo

    View Full Article Hide Full Article
  2. FREMONT, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration ("FDA") regarding the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application ("NDA") following receipt of preliminary top-line results from the pharmacokinetic ("PK") study.

    The PK study included 48 healthy volunteers and evaluated approximately 2,500 samples utilizing lots of M207 produced with two different pieces of manufacturing equipment ("equipment A" and "equipment B"). The study was designed to evaluate safety and the pharmacokinetics…

    FREMONT, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration ("FDA") regarding the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application ("NDA") following receipt of preliminary top-line results from the pharmacokinetic ("PK") study.

    The PK study included 48 healthy volunteers and evaluated approximately 2,500 samples utilizing lots of M207 produced with two different pieces of manufacturing equipment ("equipment A" and "equipment B"). The study was designed to evaluate safety and the pharmacokinetics of drug exposure levels compared to an intranasal control formulation of two 5 mg doses of zolmitriptan. The safety assessment showed that M207 was generally well tolerated, consistent with previous studies. The preliminary data from the PK analysis showed that there were no outliers with unexpected high plasma concentrations of zolmitriptan, which was a focus of the FDA, as identified in the Complete Response Letter for the original M207 NDA. Drug plasma concentration levels from M207 produced with equipment A were within range and comparable to the intranasal control. Drug plasma concentration levels of M207 produced with equipment B were lower compared to control and to M207 produced by equipment A, but within ranges consistent with approved therapeutic dose levels of zolmitriptan. The FDA had also raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of M207 in the company's clinical trials.

    "We are pleased that the preliminary top-line PK study results did not identify any outliers with unexpected high plasma concentrations of zolmitriptan," said Steven Lo, president and chief executive officer of Zosano. "We requested a meeting with the FDA to review the data, including the preliminary bioequivalence data from the lots produced with the different manufacturing equipment, and, following written feedback from the FDA from the Type C meeting, we plan to refine our strategy for the resubmission of an NDA. We look forward to providing an update on our resubmission plans after we receive written feedback from the FDA, which is expected to occur by mid-December. There are thousands of people experiencing migraine attacks in the U.S. that are not adequately served by existing therapies, and we believe in the potential of M207 to provide much-needed relief from this disease."

    Unless and until the company resubmits an NDA and potentially receives FDA approval, the company is unable to estimate a timeframe for product launch or revenues for 2022, if any, or beyond.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Previously, M207 was known as Qtrypta, which the company no longer intends to use as the proprietary name of M207. The company is currently in the process of identifying an alternative proprietary name for M207. Learn more at www.zosanopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding preliminary results from the company's pharmacokinetic study, the timing of written feedback from the Type C meeting with the FDA and strategies for resubmission of the NDA for M207, the potential benefits and availability of M207 for patients, the expectations for identifying a proprietary name for M207 and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "scheduled," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company's ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

    Zosano Contacts:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    Zosano PR:

    Sylvia Wheeler or Alexandra Santos

     or 



    Primary Logo

    View Full Article Hide Full Article
  3. FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference available on demand beginning September 13, 2021 at 7:00am ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma
    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules…

    FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference available on demand beginning September 13, 2021 at 7:00am ET.

    A live webcast of the event will be available on the company's website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.

    Zosano Contacts:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    Zosano PR:

    Sylvia Wheeler or Alexandra Santos

    or



    Primary Logo

    View Full Article Hide Full Article
  4. FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

    "We are pleased to have initiated the healthy volunteer pharmacokinetic study that was requested by the FDA for the resubmission of the New Drug Application (NDA) for M207," said Steven Lo, president and chief executive officer of Zosano. "The study is evaluating pharmacokinetics and safety in approximately 48 healthy volunteers. We are diligently working to complete this study in the third quarter. Pending receipt of positive data, we plan to resubmit the NDA for M207 by year-end. Additionally…

    FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

    "We are pleased to have initiated the healthy volunteer pharmacokinetic study that was requested by the FDA for the resubmission of the New Drug Application (NDA) for M207," said Steven Lo, president and chief executive officer of Zosano. "The study is evaluating pharmacokinetics and safety in approximately 48 healthy volunteers. We are diligently working to complete this study in the third quarter. Pending receipt of positive data, we plan to resubmit the NDA for M207 by year-end. Additionally, this quarter we strengthened our patent portfolio with the issuance of a U.S. patent covering method of use of M207."

    Select Business Highlights

    • Initiated the pharmacokinetic study required to support the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) NDA
    • Announced publication of an article titled, "Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine" in The Journal of Headache and Pain highlighting the positive safety and efficacy results from this long-term study
    • Received notification of a newly issued U.S. patent for method of rapidly achieving therapeutic levels with M207 for the acute treatment of migraine
    • Appointed Kathy McGee, an accomplished biopharmaceutical executive currently serving as the chief operating officer of AVITA MEDICAL, to the board of directors

    Financial Results for the Second Quarter Ended June 30, 2021

    Zosano reported a net loss for the second quarter of 2021 of $6.1 million, or $0.06 per share on a basic and diluted basis, compared with a net loss of $7.9 million, or $0.14 per share on a basic and diluted basis, for the same quarter in 2020. The net loss for the second quarter of 2021 included a $1.6 million gain on the forgiveness of our Paycheck Protection Loan.

    Research and development expenses for the second quarter of 2021 were $5.0 million, compared with $4.9 million for the same quarter in 2020. The increase was primarily due to an increase of $0.2 million in manufacturing costs related to the scale up and technology transfer to our commercial manufacturing organizations and $0.2 million in increased spending for clinical trials. These increases were partially offset by a decrease of $0.3 million in employee and consulting costs.

    General and administrative expenses for the second quarter of 2021 were $3.0 million compared with $2.8 million for the same quarter in 2020. The increase of $0.2 million was primarily due to higher employee related costs.

    As of June 30, 2021, cash and cash equivalents were $22.1 million, compared with $35.3 million as of December 31, 2020.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Previously, M207 was known as Qtrypta, which the company no longer intends to use as the proprietary name of M207. The Company is currently in the process of identifying an alternative proprietary name for M207. Learn more at www.zosanopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company's ongoing pharmacokinetic study and the anticipated timing with respect to the study; the expected timing of the potential resubmission of the NDA for M207, the potential benefits and availability of M207 for patients, the expectations for identifying a proprietary name for M207 and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "scheduled," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company's ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

    Zosano Contacts:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    Zosano PR:

    Sylvia Wheeler or Alexandra Santos

     or 





    ZOSANO PHARMA CORPORATION

    BALANCE SHEETS

    (in thousands, except par value and share amounts)

     June 30,

    2021
     December 31,

    2020
     (unaudited)  
    ASSETS
    Current assets:   
    Cash and cash equivalents$22,058  $35,263 
    Prepaid expenses and other current assets1,787  453 
    Total current assets23,845  35,716 
    Restricted cash455  455 
    Property and equipment, net32,184  30,909 
    Operating lease right-of-use assets4,366  4,928 
    Other long-term assets  3 
    Total assets$60,850  $72,011 
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:   
    Accounts payable$1,677  $1,884 
    Accrued compensation1,801  2,294 
    Build-to-suit obligation, current portion, net of debt issuance costs and discount4,825  4,779 
    Operating lease liabilities, current portion1,492  1,378 
    Paycheck Protection Program loan, current portion  809 
    Other accrued liabilities1,620  3,367 
    Total current liabilities11,415  14,511 
    Build-to-suit obligation, long-term portion, net of debt issuance costs and discount2,237  4,359 
    Operating lease liabilities, long-term portion3,911  4,687 
    Paycheck Protection Program loan, long-term portion  812 
    Other long-term liabilities221  127 
    Total liabilities17,784  24,496 
        
    Stockholders' equity:   
    Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2021 and December 31, 2020, respectively   
    Common stock, $0.0001 par value; 250,000,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 113,329,291 and 102,066,218 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively11  10 
    Additional paid-in capital389,531  379,695 
    Accumulated deficit(346,476) (332,190)
    Total stockholders' equity43,066  47,515 
    Total liabilities and stockholders' equity$60,850  $72,011 





    ZOSANO PHARMA CORPORATION

    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except per share amounts)

    (unaudited)

     Three Months Ended June 30, Six Months Ended June 30,
     2021 2020 2021 2020
            
    Service revenue$188  $  $446  $ 
    Operating expenses:       
    Cost of service revenue202    364   
    Research and development5,000  4,932  10,330  10,446 
    General and administrative2,958  2,766  5,772  5,848 
    Total operating expenses8,160  7,698  16,466  16,294 
    Loss from operations(7,972) (7,698) (16,020) (16,294)
    Other income (expense):       
    Interest income  5  1  15 
    Interest expense(22) (190) (119) (396)
    Other income (expense), net1,850  (12) 1,852  91 
    Loss before provision for income taxes(6,144) (7,895) (14,286) (16,584)
    Provision for income taxes       
    Net loss and comprehensive loss$(6,144) $(7,895) $(14,286) $(16,584)
            
    Net loss per common share – basic and diluted$(0.06) $(0.14) $(0.13) $(0.36)
    Weighted-average common shares used in computing net loss per common share – basic and diluted108,943  54,927  106,662  45,597 



    Primary Logo

    View Full Article Hide Full Article
  5. FREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines.

    "As we continue to execute on completing the pharmacokinetic study for the potential resubmission of our NDA for M207, we are very pleased to strengthen our patent portfolio for our innovative product candidate," said Steven Lo, president and chief executive officer of Zosano. "We believe M207, if approved, may represent an attractive therapeutic option for patients…

    FREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines.

    "As we continue to execute on completing the pharmacokinetic study for the potential resubmission of our NDA for M207, we are very pleased to strengthen our patent portfolio for our innovative product candidate," said Steven Lo, president and chief executive officer of Zosano. "We believe M207, if approved, may represent an attractive therapeutic option for patients with debilitating migraines and look forward to further discussions with the FDA as we continue to seek approval."

    The newly issued patent covers methods for the release of active drug from Zosano's microneedle system in about one minute and reaching potentially therapeutic levels as quickly as 30 minutes upon application. This latest patent adds to Zosano's M207 patent portfolio, which now includes two U.S. patents with claims covering composition of matter and method of use for M207 with expirations in 2037.

    About M207

    M207 is Zosano's proprietary investigational formulation of zolmitriptan delivered utilizing its proprietary transdermal microneedle system (the "System") in development for the acute treatment of migraine. The System consists of titanium microneedles coated with drug, and in the case of M207, the formulation is zolmitriptan. The drug-coated microneedles are designed to penetrate the stratum corneum, where the investigational drug potentially dissolves and enters into the bloodstream. In February 2017, the company announced statistically significant results from the ZOTRIP pivotal study, in which the 3.8 mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.

    About Migraine

    Migraine is a highly prevalent neurological disease impacting 12% of the US population and 1 in 4 households. Patients impacted by migraine experience significant disability, with 90% unable to function normally.  Migraine attacks are estimated to lead to lost productivity costs as high as $36 billion annually in the United States, including both direct and indirect costs. Zosano believes there is a significant need for new acute treatment options since 74% of migraine patients experience inadequate treatment response.

    About Zosano Pharma

    Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company's ongoing pharmacokinetic study and its potential resubmission of the NDA for M207, the potential benefits and availability of M207 for patients and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company's ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

    Zosano Contacts:

    Christine Matthews

    Chief Financial Officer

    510-745-1200

    Zosano PR:

    Sylvia Wheeler or Alexandra Santos

     or 



    Primary Logo

    View Full Article Hide Full Article
View All Zosano Pharma Corporation News